Jardiance weight loss
Pro Research Analysisby 
Searched over 200M research papers
Jardiance (Empagliflozin) and Weight Loss
Introduction to Jardiance (Empagliflozin)
Jardiance, known generically as empagliflozin, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for the treatment of type 2 diabetes mellitus (T2DM). This medication works by inhibiting the reabsorption of glucose in the renal tubules, promoting glucosuria, which is the excretion of glucose in the urine. This mechanism not only helps in controlling blood sugar levels but also has additional benefits, including weight loss and cardiovascular protection 12.
Mechanism of Action and Weight Loss
Glucose Excretion and Caloric Loss
Empagliflozin's primary action is to block SGLT2 in the kidneys, which prevents glucose from being reabsorbed back into the bloodstream. Instead, glucose is excreted through urine. This process leads to a loss of calories, which contributes to weight reduction. Clinical trials have shown that patients taking empagliflozin experience a significant reduction in body weight, averaging around 2 kg over a period of 24 to 104 weeks .
Osmotic Diuresis and Blood Pressure Reduction
In addition to promoting weight loss through caloric excretion, empagliflozin induces osmotic diuresis, which helps in lowering arterial blood pressure. This diuretic effect can also contribute to weight loss by reducing fluid retention in the body .
Clinical Evidence Supporting Weight Loss
Controlled Trials and Comparative Studies
Empagliflozin has been extensively studied in controlled trials. These studies have consistently demonstrated its efficacy in reducing body weight in patients with T2DM. For instance, in trials lasting from 24 to 104 weeks, empagliflozin not only improved glycemic control but also led to a significant reduction in body weight compared to placebo and other active comparators like metformin, glimepiride, and sitagliptin .
Comprehensive Reviews and Meta-Analyses
Comprehensive reviews of SGLT2 inhibitors, including empagliflozin, have reinforced these findings. These reviews highlight that empagliflozin is effective in managing weight loss in patients with diabetes mellitus, alongside its cardio-protective and reno-protective effects. The drug's pharmacokinetic profile shows no major drug interactions and minimal side effects, making it a favorable option for long-term management of T2DM and associated weight issues .
Conclusion
Empagliflozin (Jardiance) is a highly effective SGLT2 inhibitor that not only helps in controlling blood sugar levels in patients with type 2 diabetes but also promotes weight loss through mechanisms of glucose excretion and osmotic diuresis. Clinical trials and comprehensive reviews have consistently shown that empagliflozin leads to significant weight reduction, making it a valuable addition to diabetes management protocols. Its additional benefits, such as cardiovascular and renal protection, further enhance its therapeutic profile, offering a multifaceted approach to managing T2DM.
Sources and full results
Most relevant research papers on this topic